Primary treatment of Crohn’s disease: combined antibiotics taking center stage

References

• Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis.12(7), 651–664 (2006).
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med.347, 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Akbulut S, Yavuz B, Koseoglu T et al. Crohn’s disease with isolated esophagus and gastric involvement. Turk. J. Gastroenterol.15(3), 196–200 (2004).
   Google Scholar
• Malleson P. Isolated gastroduodenal Crohn’s disease in a ten-year-old girl. Postgrad. Med. J.56, 294–296 (1980).
   Google Scholar
• Kotanagi H, Sone S, Fukuoka T et al. Liver abscess as the initial manifestation of colonic Crohn’s disease: report of a case. Surgery Today21(3), 348–351 (2007).
   Google Scholar
• Ulnick KM, Perkins J. Extraintestinal Crohn’s disease: case report and review of the literature. Ear Nose Throat J.80(2), 97–100 (2001).
   PubMedGoogle Scholar
• Sartor BR. Pathogenesis of Crohn’s disease and ulcerative colitis: specific theories. Nat. Clin. Prac. Gastroenterol. Hepatol.3(7), 390–407 (2006).
   PubMedGoogle Scholar
• Blichfeldt P, Blonhoff JP, Myhre E et al. Metronidazole in Crohn’s disease. A double-blind cross-over clinical trial. Scand. J. Gastroenterol.13, 123–127 (1978).
   PubMed Web of Science ®Google Scholar
• Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II Result. Gastroenterology83, 550–562 (1982).
   PubMed Web of Science ®Google Scholar
• Ambrose NS, Allan RN, Keighley MR et al. Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. Dis. Colon Rectum28, 81–85 (1985).
   PubMed Web of Science ®Google Scholar
• Sutherland L, Singleton J, Sessions J et al. Double-blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut32, 1071–1075 (1991).
   PubMed Web of Science ®Google Scholar
• De’Haens GR, Vermeire S, Van Assche G et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology135(4), 1123–1129 (2008).
   Google Scholar
• Feller M, Huwiler K, Schoepfer A et al. Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect Dis.50(4), 473–480 (2010).
   PubMed Web of Science ®Google Scholar
• Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn’s disease? J. Clin. Gatroenterol.17, 235–237 (1993).
   PubMed Web of Science ®Google Scholar
• Arnold GL, Beaves MR, Pyrjdun VO et al. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm. Bowel Dis.8, 10–15 (2002).
   PubMed Web of Science ®Google Scholar
• Prantera C, Zannoni F, Scribano ML et al. An antibiotic treatment regimen for the treatment of active Crohn’s disease. A randomized controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol.91, 328–332 (1996).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Lehman M, Cassagnou M et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETARD). Am. J. Gastroenterol.94, 674–678 (1999).
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and antibiotic therapy for active Crohn’s disease. A randomized controlled trial. Gastroenterology123, 33–40 (2002).
   PubMed Web of Science ®Google Scholar
• Prantera C, Berto E, Scribano ML et al. Use of antibiotics in the treatment of active Crohn’s disease. Experience with metronidazole and ciprofloxacin. Ital. J. Gastroenterol. Hepatol.30, 602–606 (1998).
   PubMed Web of Science ®Google Scholar
• Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can. J. Gastroenterol.12, 53–56 (1998).
   PubMed Web of Science ®Google Scholar
• Khan K, Ullman T, Ford A et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol.106(4), 661–673 (2011).
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s Disease: current management. J. Crohn’s Colitis4, 28–62 (2010).
   Google Scholar
• Shafran I. Burgeunder P. Rifaximin for the treatment of newly diagnosed Crohn’s disease: a case series. Am. J. Gasteroenterol.103, 2158–2160 (2008).
   Google Scholar
• Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr. Med. Res. Opin.21, 1165–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn’s disease activity. Dig. Dis. Sci.55, 1079–1084 (2010).
   PubMed Web of Science ®Google Scholar
• Warren J, Rees H, Cox T. Remission of Crohn’s disease with tuberculosis chemotherapy. N. Engl. J. Med.314, 182 (1986).
   PubMed Web of Science ®Google Scholar
• Schultz M, Rieder H, Hersh T et al. Remission of Crohn’s disease with antibacterial chemotherapy. Lancet330, 1391–1392 (1987).
   Google Scholar
• Ward M, McManus JP. Dapsone in Crohn’s disease. Lancet1, 1236–1237 (1975).
   Google Scholar
• Prantera C, Argentieri R, Mangiarotti R et al. Dapsone and remission of Crohn’s disease. Lancet1(8584), 536 (1988).
   Google Scholar
• Prantera C, Bothamley G, Levenstein S et al. Crohn’s disease and mycobacteria: two cases of Crohn’s disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Biomed. Pharmacother.43(4), 295–299 (1989).
   Google Scholar
• Shaffer JL, Hughes S, Linaker BD et al. Controlled trial of rifampicin and ethambutol in Crohn’s disease. Gut25, 203–205 (1984).
   PubMedGoogle Scholar
• Jarnerot G, Rolny P, Wickbom G et al. Antimycobacterial therapy ineffective in Crohn’s disease after a year. Lancet1, 164–165 (1989).
   Google Scholar
• Swift GL, Srivastava ED, Stone R et al. Controlled trial of anti-tuberculosis chemotherapy for two years in Crohn’s disease. Gut.35, 363–368 (1994).
   PubMedGoogle Scholar
• Rutgeerts P, Geboes K, Vantrappen G et al. Rifabutin and ethambutol do not help recurrent Crohn’s disease in the neoterminal ileum. J. Clin. Gastroenterol.15, 24–28 (1992).
   PubMedGoogle Scholar
• Hampson S, Parker M, Saverymutter S et al. Quadruple antimycobacterial chemotherapy in Crohn’s disease: results at 9 months of a pilot study in 20 patients. Aliment. Pharmacol. Ther.3(4), 343–352 (1989).
   PubMed Web of Science ®Google Scholar
• Prantera C, Kohn A, Mangiarotti R et al. Antimycobacterial therapy in Crohn’s disease: results of a controlled double-blind trial with a multiple antibiotic regimen. Am. J. Gastroenterol.89(4), 513–518 (1994).
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Long A, Lennon J et al. Controlled trial of antimycobacterial therapy in Crohn’s disease: clofazimine versus placebo. Dig. Dis. Sci.36, 449–453 (1991).
   PubMed Web of Science ®Google Scholar
• Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn’s disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology108, A826 (1995).
   Web of Science ®Google Scholar
• Leiper M. Open label trial of oral clarithromycin in active Crohn’s disease. Aliment. Pharmacol. Ther.14(6), 801–806 (2000).
   PubMedGoogle Scholar
• Inoue S, Nakase H, Matsuura M et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn’s disease. J. Gastro. Hepatol.22, 984–988 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Bishop A, Cafaro A et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann. Thorac. Surg.85, 1887–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Gangadharam PR, Perumal, VK, Jairam, BT et al. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am. Rev. Respir. Dis.136, 329–333 (1987).
   Google Scholar
• Hornick DB, Dayton CS, Bedell GN et al. Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach. Chest93(3), 550–555 (1988).
   PubMedGoogle Scholar
• Chiodini RJ. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains Mycobacterium avium paratuberculosis. J. Antimicrob. Chemother.27, 171–176 (1991).
   PubMed Web of Science ®Google Scholar
• Blasquez J, Oliver A, Gomez-Gomez JM. Mutation and evolution of antibiotic resistance: antibiotics as promoters of antibiotic resistance? Curr. Drug Targets3(4), 345–349 (2002).
   Google Scholar
• Ghebremichael S, Svenson SB, Kallenius G et al. Antimycobacterial synergism of clarithromycin and rifabutin. Scan. J. Infect. Dis.28, 387–390 (1996).
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement its extracellular and intracellular activities by ethambutol. Antimicrob. Agents Chemother.36, 2843–2846 (1992).
   PubMed Web of Science ®Google Scholar
• Gui GPH, Thomas PRS, Tizard MLV et al. Two-year outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother.39(3), 393–400 (1997).
   PubMed Web of Science ®Google Scholar
• Douglas A, Bramble MG, Silcock JC. Antimycobacterial treatment for Crohn’s disease: does it prevent surgery and how fast does it act? Gut48, A89 (2000).
   Google Scholar
• Borody TJ, Leis S, Warren EF et al. Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Dig. Liver Dis.34(1), 29–38 (2002).
   PubMedGoogle Scholar
• Shafran I, Kugler L, El-Zaatari FA et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig. Liver Dis.34(1), 22–28 (2002).
   PubMedGoogle Scholar
• Borody TJ, Bilkey S, Wettstein AR et al.Australian Gastroenterology Week Meeting. Brisbane, Queensland, Australia, 19–22 October 2005.
   Google Scholar
• Borody TJ, Bilkey S, Wettstein AR et al. Anti-mycobacterial therapy in Crohn’s disease heals mucosa with longitudinal scars. Dig. Liver Dis.39(5), 438–444 (2007).
   PubMedGoogle Scholar
• Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin and clofazimine for Crohn’s disease. Gastroenterology132(7), 2313–2319 (2007).
   PubMed Web of Science ®Google Scholar
• Behr M, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn’s disease. Curr. Opin. Gastroenterol.24(1), 17–21 (2008).
   PubMed Web of Science ®Google Scholar
• Biroulet LP, Neut C, Colombel JF. Antimycobacterial therapy in Crohn’s disease: the end of a long controversy? Prac. Gastro.1, 11–17 (2008).
   Google Scholar
• Yunzhao RR, Pan F, Parvez S et al. Clofazamine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One3(12), e4009 (2008).
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomised trial. Lancet359, 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Keunstner J. Australian Crohn’s Antibiotic Study opens new horizons. Gastroenterology133(5), 1743–1744 (2007).
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Furberg CD et al. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch. Intern. Med.167(16), 1752–1759 (2007).
   PubMed Web of Science ®Google Scholar
• Lees C, Ali A, Thompson AI, Ho GT et al. The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther.29(3), 286–297 (2009).
   PubMed Web of Science ®Google Scholar
• Chamberlin W, Ghobrial G, Chehtane M et al. Successful treatment of a Crohn’s disease patient infected with bacteremic Mycobacterium paratuberculosis. Am. J. Gastroenterol.102, 689–691 (2007).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Shekoufeh N, Rezaie A et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin. Ther.28(12), 1983–1988 (2006).
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA. A NOD for autophagy. Nature Med.16, 28–30 (2010).
   Google Scholar
• Hayee B, Rahman F, Sewell G et al. Crohn’s disease as an immunodeficiency. Expert Rev. Clin. Immunol.6(4), 585–596 (2010).
   PubMed Web of Science ®Google Scholar
• Korzenik JR, Dieckgraefe BK, Valentine JF et al. Sargramostim for active Crohn’s disease. N. Engl. J. Med.352, 2193–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Conrad D, Wang A et al. 16α-bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. Clin. Exp. Immunol.158(3), 308–316 (2009).
   Google Scholar
• Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat. Rev. Micro.2, 166–173 (2004).
   PubMed Web of Science ®Google Scholar